Living Donor Medical Evaluation

This evaluation must be completed:	Including evaluation for and assessment of this information:
General donor history	A personal history of significant medical condition which include but are not limited to: Hypertension Diabetes Lung disease Heart disease Gastrointestinal disease Autoimmune disease Neurologic disease Genitourinary disease Hematologic disorders History of cancer including melanoma History of infections Active and past medications with special consideration for known nephrotoxic and hepatotoxic medications or chronic use of pain medication Allergies An evaluation for coronary artery disease
General family history	Coronary Artery Disease Cancer
Social history	 Occupation Employment status Health insurance status Living arrangements Social support Smoking, alcohol, and drug use and abuse Psychiatric illness, depression, suicide attempts Increased risk behavior as defined by the U.S. Public Health Services (PHS) Guideline
hysical Exam	 Height Weight Body Mass Index (BMI) Vital signs Examination of all major organ systems
eneral Laboratory and imaging tests	 Complete blood count (CBC) with platelet count Blood type and subtype Prothrombin Time (PT) or International Normalized Ratio (INR) Partial Thromboplastin Time (PTT)

General Laboratory and imaging tests (cont'd)	 Metabolic testing (to include: electrolytes, BUN, creatinine, transaminase levels, albumin, calcium, phosphorus, alkaline phosphatase, bilirubin HCG quantitative pregnancy test for premenopausal women without surgical sterilization Chest X-Ray Electrocardiogram (ECG)
Transmissible disease screening	Infectious disease testing must include all of the
	following:
	Cytomegalovirus (CMV) antibody
	2. Epstein Barr Virus (EBV) antibody
	3. HIV antibody (anti-HIV) testing or HIV
	antigen/antibody (Ag/Ab) combination
	test as close as possible, but within 28
	days to organ recovery
	4. Hepatitis B surface antigen (HBsAg) testing
	as close as possible, but within 28 days
	prior to organ recovery
	5. Hepatitis B core antibody (anti-HBc)
	testing as close as possible but within 28
	days prior to organ recovery
	6. Hepatitis C antibody (anti-HCV) testing as
	close as possible, but within 28 days prior
	to organ recovery
	7. Syphilis testing
	For Tuberculosis (TB), living donor recovery
	hospitals must determine if the donor is at
	increased risk for this infection. If TB risk is
	suspected, testing must include screening for
	latent infection using either:
	Intradermal PPD
	Interferon Gamma Release Assay (IGRA)
Endemic transmissible diseases	Each living donor hospital must develop and follow
	a written protocol for identifying and testing
	donors at risk for transmissible seasonal or
	geographically defined endemic disease as part of
	its medical evaluation.
Cancer screening	Recovery hospitals must develop and comply with
	protocols consistent with the American Cancer
	Society (ACS) or the U.S. Preventative Services
	Task Force to screen for:
	Cervical cancer
	Breast cancer
	Prostate cancer
	Colon cancer
	Lung cancer

Kidney- specific donor history	A personal history of significant medical condition which include, but are not limited to, kidney-specific personal history including:
Kidney- specific family history	 Kidney disease Diabetes Hypertension Kidney cancer
Physical exam	Blood pressure taken on at least two different occasions or 24-hour or overnight blood pressure monitoring.
Other metabolic testing	 Fasting blood glucose Fasting lipid profile (cholesterol, triglycerides, HDL cholesterol, and LDL cholesterol) Glucose tolerance test of glycosylated hemoglobin in first degree relatives of diabetics and in high risk individuals
Kidney- specific tests	 Urinalysis or urine microscopy Urine culture if clinically indicated Measurement of urinary protein and albumin excretion Measurement of glomerular filtration rate by isotopic methods or a creatinine clearance calculated from a 24-hour urine collection Hospitals must develop and comply with a written protocol for polycystic kidney disease or other inherited renal disease as indicated by family history. Patients wit a history of nephrolithiasis or nephrolithiasis (>3mm) identified on radiographic imaging must have a 24-hour urine stone panel measuring: Calcium Oxalate Uric acid Citric acid Creatinine Sodium
natomic assessment	Determine: • Whether the kidneys are of equal size • If the kidneys have masses, cysts, or

Anatomic assessment (cont'd)	stones
	If the kidneys have other anatomical defects
	Which kidney is more anatomically suited for transplant